Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDanyang LiZFZhonghua FuFYFan Yang

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals promising clinical outcomes for CAR-T therapy in CNS lymphoma patients with TP53 mutations, indicating potential treatment options.

Key Points

  • CAR-T therapy shows efficacy in CNS lymphoma with TP53 mutations, especially in non-GCB subtype patients.
  • Overall response rate for TP53+CAR-T+ patients was 64.5%, comparable to traditional therapies.
  • Retrospective cohort study analyzed 61 CNS lymphoma patients between 2020 and 2024.
  • These findings emphasize the need for tailored treatment plans based on genetic factors such as TP53 status.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec4https://doi.org/10.1182/blood-2025-3708
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma2025 · 1 citations
  2. 2Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025
  3. 3Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2025
  4. 4Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  5. 5Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.2025 · 2 citations